A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of UB-221 as an Add-on Therapy in Patients With Chronic Spontaneous Urticaria
Phase of Trial: Phase I
Latest Information Update: 05 Apr 2019
Price : $35 *
At a glance
- Drugs UB 221 (Primary)
- Indications Urticaria
- Focus Adverse reactions
- Sponsors United BioPharma
- 01 Apr 2019 Status changed from not yet recruiting to recruiting.
- 10 Mar 2019 Planned initiation date changed from 1 Mar 2019 to 1 Apr 2019.
- 14 Feb 2019 Planned initiation date changed from 30 Nov 2018 to 1 Mar 2019.